Pedersen L, Bremmelgaard A
Scand J Gastroenterol. 1976;11(4):385-9.
In 9 patients with radiolucent gallstones, percutanous liver biopsy was performed during treatment with chenodeoxycholic acid in a dose of 500 to 750 mg per day for 3-14 months. In 4 patients pretreatment specimens were available for comparison. No sign of hepatic cellular necrosis or bile duct proliferation was noticed in the biopsies. In 2 patients hepatic steatosis was reduced, and in one patient moderate portal tract inflammation decreased during therapy. Mean values of alkaline phosphatases, alanine aminotransferases, prothrombin, and serum lipids remained unchanged and did not exceed normal limits. In 5 patients the urinary bile acid profile was examined during therapy. Chenodeoxycholic acid constituted 27-50%, lithocholic acid 25-63%, and ursodeoxycholic acid 0-13% of total bile acids in urine. The renal excretion of total bile acids was estimated to be less than two mg per day in each patient. From 86 to 100 per cent of the bile acids in urine was sulfated.
9例有透X线胆结石的患者，在接受每天500至750毫克鹅去氧胆酸治疗3至14个月期间进行了经皮肝活检。4例患者有治疗前标本可供比较。活检中未发现肝细胞坏死或胆管增生的迹象。2例患者的肝脂肪变性减轻，1例患者在治疗期间中度门静脉炎症减轻。碱性磷酸酶、丙氨酸转氨酶、凝血酶原和血脂的平均值保持不变，且未超过正常范围。5例患者在治疗期间检查了尿胆汁酸谱。尿中鹅去氧胆酸占总胆汁酸的27%至50%，石胆酸占25%至63%，熊去氧胆酸占0%至13%。估计每位患者每天尿中总胆汁酸的排泄量少于2毫克。尿中86%至100%的胆汁酸被硫酸化。
